title: The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response.
abstract: Despite significant advances in the understanding of tissue responses to biomaterials, most implants are still plagued by inflammatory responses which can lead to fibrotic encapsulation. This is of dire consequence in tissue engineering, where seeded cells and bioactive components are separated from the native tissue, limiting the regenerative potential of the design. Additionally, these interactions prevent desired tissue integration and angiogenesis, preventing functionality of the design. Recent evidence supports that mesenchymal stem cells (MSC) and hematopoietic stem cells (HSC) can have beneficial effects which alter the inflammatory responses and improve healing. The purpose of this study was to examine whether stem cells could be targeted to the site of biomaterial implantation and whether increasing local stem cell responses could improve the tissue response to PLGA scaffold implants. Through incorporation of SDF-1alpha through factor adsorption and mini-osmotic pump delivery, the host-derived stem cell response can be improved resulting in 3X increase in stem cell populations at the interface for up to 2 weeks. These interactions were found to significantly alter the acute mast cell responses, reducing the number of mast cells and degranulated mast cells near the scaffold implants. This led to subsequent downstream reduction in the inflammatory cell responses, and through altered mast cell activation and stem cell participation, increased angiogenesis and decreased fibrotic responses to the scaffold implants. These results support that enhanced recruitment of autologous stem cells can improve the tissue responses to biomaterial implants through modifying/bypassing inflammatory cell responses and jumpstarting stem cell participation in healing at the implant interface.
authors.affiliation: Bioengineering Department, University of Texas at Arlington, Arlington, TX 76019-0138, USA.
authors.forename: Paul T
authors.initials: PT
authors.lastname: Thevenot
authors.forename: Ashwin M
authors.initials: AM
authors.lastname: Nair
authors.forename: Jinhui
authors.initials: J
authors.lastname: Shen
authors.forename: Parisa
authors.initials: P
authors.lastname: Lotfi
authors.forename: Cheng-Yu
authors.initials: CY
authors.lastname: Ko
authors.forename: Liping
authors.initials: L
authors.lastname: Tang
mesh_terms: D000818:Animals; D002465:Cell Movement / Q000187:drug effects*; D054377:Chemokine CXCL12 / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism; D005549:Foreign-Body Reaction / Q000473:pathology; D019650:Hematopoietic Stem Cell Mobilization; D020007:Implants, Experimental; D007249:Inflammation / Q000473:pathology*; D019344:Lactic Acid / Q000494:pharmacology*; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C; D011100:Polyglycolic Acid / Q000494:pharmacology*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: D054377:Chemokine CXCL12; D016207:Cytokines; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid